Literature DB >> 6270308

Alpha and beta adrenergic effects of the stereoisomers of dobutamine.

R R Ruffolo, T A Spradlin, G D Pollock, J E Waddell, P J Murphy.   

Abstract

Dobutamine and its stereoisomers were evaluated for alpha and beta adrenergic activities in vitro. The racemate and the (--)-isomer were found to be potent partial agonists of alpha adrenergic receptors in rat aorta. The (+)-isomer lacked alpha agonist activity. The affinities of (+/-)-, (+)- and (--)-dobutamine for the alpha adrenergic receptor were high (--log KB values of 7.01, 7.02 and 7.07, respectively) and not significantly different from one another. These data indicate that (+)- and (--)- dobutamine bind equally to the alpha adrenergic receptor, however, subsequent to binding, only the (--)-isomer is capable of activating the receptor and eliciting an alpha adrenergic response. The (+)-isomer, which has the same affinity as the (--)-isomer but which lacks agonist activity, is a potent competitive alpha blocker. Both stereoisomers of dobutamine were agonists of beta adrenergic receptors of cat papillary muscle and right atria. In contrast to the alpha adrenergic effects, the more potent isomer at the beta adrenergic receptor was (+)- dobutamine. The isomeric activity ratio for the stereoisomers of dobutamine was approximately 1 log unit in favor of the (+)-isomer with respect to both inotropic and chronotropic responses. Dose-response curves to the racemate were always situated between the stereoisomers, approximately 2-fold to the right of (+)-dobutamine. These results indicate that the stereochemical requirements of alpha and beta adrenergic receptors are opposite for the stereoisomers of dobutamine with the alpha receptor favoring the (--)-isomer and the beta receptor favoring the (+)-isomer.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6270308

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

2.  A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent.

Authors:  R Nagarajan; G Abou-Mohamed; T Myers; R W Caldwell
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 3.  Acute circulatory support.

Authors:  M J Barnard; S P Linter
Journal:  BMJ       Date:  1993-07-03

Review 4.  Dobutamine stress echocardiography: safety in diagnosing coronary artery disease.

Authors:  F Lattanzi; E Picano; E Adamo; A Varga
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

5.  Pharmacological characterization and anatomical localization of prejunctional beta-adrenoceptors in the rat kidney.

Authors:  P P Lakhlani; F Amenta; P Napoleone; L Felici; D C Eikenburg
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

Review 6.  Inotropic support of the critically ill patient. A review of the agents.

Authors:  P J Kulka; M Tryba
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  Platelet beta-adrenoceptors.

Authors:  R Kerry; M C Scrutton
Journal:  Br J Pharmacol       Date:  1983-07       Impact factor: 8.739

8.  Interactions of three inotropic agents, ASL-7022, dobutamine and dopamine, with alpha- and beta-adrenoceptors in vitro.

Authors:  R R Ruffolo; K Messick; J S Horng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-07       Impact factor: 3.000

Review 9.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Blockade and postjunctional vascular alpha 1- and alpha 2-adrenoceptors in pithed rat by the enantiomers of WB-4101.

Authors:  R R Ruffolo; W L Nelson; E L Yaden
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.